Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
6 min read
Cellino Biotech, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Cellino Biotech, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Castle Creek Biosciences, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Castle Creek Biosciences, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Carolus Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Carolus Therapeutics, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
CASI Pharmaceuticals, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of CASI Pharmaceuticals, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
CEL-SCI Corp. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of CEL-SCI Corp., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Cell Source, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Cell Source, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Can-Fite BioPharma Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Can-Fite BioPharma Ltd., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Cancer Advances, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Cancer Advances, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
CanBas Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of CanBas Co., Ltd., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Cancer Prevention Pharmaceuticals, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Cancer Prevention Pharmaceuticals, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Carmot Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Carmot Therapeutics, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Calithera Biosciences, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Calithera Biosciences, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.